Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
INSM · Nasdaq · United States · Pharmaceutical Preparations
In shortINSMED Inc is loss-making, burns cash and holds more cash than debt, with revenue growing (+66.7% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -205.6% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -210.5% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -249.3% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -77.0% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 3.83× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.73× | 70/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -14.88× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -7.47 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -159.6% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 20.8% | 34/100 |
| Operating margin volatility | 23.2% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 35.2% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 188 | 245 | 305 | 364 | 606 |
| Cost of revenue | 44 | 55 | 66 | 86 | 123 |
| Gross profit | 144 | 190 | 240 | 278 | 483 |
| Research & development | 273 | 398 | 571 | 598 | 771 |
| Selling, general & admin | – | 266 | 345 | 461 | 701 |
| Operating income | (375) | (457) | (710) | (878) | (1,247) |
| Interest expense | 40 | 26 | 82 | 85 | 84 |
| Pre-tax income | (436) | (480) | (747) | (910) | (1,272) |
| Income tax | (1.8) | 1.4 | 2.6 | 3.7 | 5 |
| Net income | (435) | (482) | (750) | (914) | (1,277) |
| Diluted EPS | −$3.88 | −$3.91 | −$5.34 | −$5.57 | −$6.42 |
| Diluted shares (millions) | 112 | 123 | 140 | 164 | 199 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
−7.47 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 6, 2026